Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: March 13, 2026
Subject: FDA approval of expanded age indication for GSK's RSV vaccine, Arexvy.
Key Financial Metrics
This filing is a regulatory announcement regarding product approval and does not contain financial statements. The text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Developments
- Regulatory Expansion: The US FDA expanded the approved indication for Arexvy (Respiratory Syncytial Virus vaccine, adjuvanted) to include adults aged 18 to 49 years at increased risk for lower respiratory tract disease (LRTD) caused by RSV.
- Previous Indication: Previously approved for adults aged 60 and older, and adults aged 50-59 at increased risk.
- Market Opportunity: An estimated 21 million US adults under 50 have at least one risk factor for severe RSV infection.
- Clinical Support: The decision was supported by Phase IIIb trial data (NCT06389487) demonstrating a non-inferior immune response in the 18-49 age group compared to those aged 60 and above.
Outlook, Risks, and Management Commentary
Management Commentary: Sanjay Gurunathan, Head of Vaccines and Infectious Diseases R&D, stated the expansion addresses a significant medical need and eases pressure on the healthcare system. GSK aims to bring RSV prevention to broader adult populations.
Outlook: GSK continues to advance regulatory submissions across multiple geographies to expand availability and support long-term growth objectives.
Risks and Contingencies:
- Forward-Looking Statements: Actual results may differ materially from projections due to risks described in GSK's 2025 Annual Report on Form 20-F.
- Product Limitations: The vaccine is not for use in pregnant individuals. A protective immune response may not be elicited in all vaccinees.
- Safety Profile: Common adverse events include injection site pain, fatigue, myalgia, headache, and arthralgia, consistent with the broader Phase III programme.
Investor Verification Checklist
- Verify the commercial launch timeline and pricing strategy for the new 18-49 age indication in the US.
- Review the "Risk Factors" section of GSK's 2025 Form 20-F for detailed regulatory and operational risks.
- Monitor upcoming regulatory submissions in other geographies to assess global market expansion potential.
- Assess the competitive landscape for RSV vaccines targeting younger adult populations.